Semaglutide production: how this weight-loss medicine is made

What the research tells us about GLP-1 and why scientists decided to copy it

The story of semaglutide production starts with a hormone your gut already releases, glucagon-like peptide-1, or GLP-1. After a meal, cells in your small intestine secrete GLP-1, which travels to the brain and pancreas to signal fullness and regulate blood sugar. Researchers working on obesity and type 2 diabetes recognised that if they could mimic this signal for longer, the therapeutic potential would be significant. The problem is that natural GLP-1 breaks down in the bloodstream within minutes.

Novo Nordisk's scientists addressed this by designing semaglutide: a 94% match to the human GLP-1 sequence, with two deliberate amino-acid substitutions that resist the enzyme (DPP-4) responsible for rapid breakdown. The STEP 1 trial, published in the New England Journal of Medicine, demonstrated that this engineered molecule (given once weekly at 2.4mg) produced an average body-weight reduction of around 15% over 68 weeks in adults with obesity. That result was what brought Wegovy to market and, eventually, to UK licensing. The NHS medicines page for semaglutide gives an accessible overview of how it works.

Understanding that semaglutide copies rather than replaces a natural process helps explain both its effects and its side-effect profile. Because GLP-1 receptors are found in the gut wall as well as the brain, activating them slows gastric emptying, which is why nausea is the most commonly reported early side effect, and it is also why what you eat during treatment can matter more than you might expect, including whether dairy products are a good fit while you are using Wegovy. The body is responding to a signal it recognises, just amplified and sustained.

The manufacturing chemistry behind Wegovy production

Producing semaglutide at scale is technically demanding. The core molecule is a peptide (a chain of 31 amino acids) assembled using a process called solid-phase peptide synthesis, where amino acids are added one at a time to a solid resin support. Once the chain is complete, it is cleaved from the resin and purified.

What distinguishes semaglutide from simpler peptides is the fatty-acid modification added to one amino acid in the chain. A C18 fatty-acid chain, connected via a linker, attaches the finished molecule to albumin, a protein that circulates abundantly in the blood. This albumin-binding is the key to Wegovy's once-weekly dosing: the molecule hitches a ride on albumin, slowing its clearance from the body and extending its half-life to approximately one week. You can read more about the full product profile for Wegovy, including how the injection and tablet formats differ.

After synthesis and purification, the active molecule is formulated into a sterile liquid and filled into the pre-filled KwikPen injectors used for subcutaneous administration. The oral Wegovy tablet (approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management) uses a different approach: semaglutide is combined with SNAC (sodium N-[8-(2-hydroxybenzoyl) aminocaprylate]), an absorption enhancer that helps the molecule survive passage through the stomach and cross the gut lining into the bloodstream. Without SNAC, virtually none of the peptide would reach circulation intact. For a full comparison of the semaglutide products available in the UK, including how they differ in administration and dosing, that page covers the detail.

Supply, quality control and what production constraints have meant for patients

Between 2023 and 2025, demand for semaglutide medicines outpaced manufacturing capacity worldwide. Novo Nordisk invested heavily in expanding production, building new facilities and scaling fermentation and chemical synthesis operations across Denmark and the United States. The UK market saw periods of limited availability, particularly for Wegovy injection, which had real effects on people already established on treatment.

This is worth understanding if you're researching these medicines for the first time. A question we hear regularly is whether shortage risk affects a private prescription. The honest answer is that supply now appears more stable for Wegovy than it was at peak shortage, though availability of any specific dose or pen format is always confirmed at the point of consultation, no reputable prescriber commits to a dose format before checking the current supply picture. If you're weighing up the cost of Wegovy as a private patient, understanding what a legitimate price covers (including the clinical assessment, prescription and quality-assured supply chain) matters as much as the headline figure. One thing the shortage years made clear: medicines obtained without a prescription and clinical assessment carry real risks, including the possibility that they are counterfeit. The MHRA has warned publicly about fake weight-loss pens seized in significant quantities in the UK.

Quality control at licensed manufacturing sites means every released batch has passed testing for purity, potency and sterility. That assurance doesn't travel with medicines sourced outside the regulated UK supply chain. Our page on who makes Wegovy explains Novo Nordisk's manufacturing infrastructure in more detail. If you've been considering treatment and want to understand whether you might be eligible, checking your eligibility through a free consultation is a sensible first step, a prescriber, not an algorithm, reviews every application.